Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Ever Supreme Bio Technology Co., Ltd. (6712) AI Stock Analysis

TW:6712

Ever Supreme Bio Technology Co., Ltd.

(TPEx:6712)

Select Model
Rating:73Outperform
Price Target:TWD 161.00â–²(8.78% Upside)
Action:initiatedcoverage
Date:11/10/26

Strong financial performance with high margins, minimal debt, and excellent cash conversion is the main positive driver. Technical weakness from price trends and MACD is partially offset by oversold conditions, while valuation appears fair.

Positive Factors
Revenue GrowthMaterial multi-year revenue scaling indicates the company has expanded its business base and maintained demand into 2025. Continued top-line growth can support operating leverage, reinvestment, and stronger competitive positioning over the next several quarters.
Negative Factors
Declining Free Cash FlowThe year-over-year free-cash-flow decline indicates that cash conversion has weakened from the prior period, potentially reflecting normalization, investment, or working-capital pressure. Persistent deterioration would reduce internally funded growth and weaken capital-allocation flexibility.

Ever Supreme Bio Technology Co., Ltd. (6712) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%TW:6712-3.75%SPY+14.30%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 14.72B
Dividend Yield
2.14%
Average Volume (3M)
251.12K
Price to Earnings (P/E)
30.9
Beta (1Y)
0.41
Revenue Growth
13.26%
EPS Growth
-15.91%
Country
TW
Employees
88
Sector
General
Sector Strength
55
Industry
Biotechnology

Ever Supreme Bio Technology Co., Ltd. Business Overview & Revenue Model

Company Description

This enterprise is dedicated to the investigation, advancement, and creation of pharmaceutical treatments leveraging human mesenchymal stem cells and immune cells. Its current portfolio features UMC01, a drug candidate undergoing Phase I clinical eva...

Ever Supreme Bio Technology Co., Ltd. Financial Statement Overview

Summary

Rapid revenue growth with high gross and net margins; very strong balance sheet with minimal debt and robust equity; excellent cash flow conversion indicating high-quality earnings.

Income Statement

84Very Positive

Balance Sheet

93Very Positive

Cash Flow

89Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.08B1.02B933.81M758.39M627.51M438.84M
Gross Profit793.91M721.33M660.04M484.75M414.56M245.48M
EBITDA550.90M462.17M491.76M655.52M300.16M433.26M
Net Income473.27M429.43M367.25M539.40M200.71M369.60M
Balance Sheet
Total Assets3.54B2.00B2.14B2.08B1.97B2.02B
Cash, Cash Equivalents and Short-Term Investments1.06B435.66M938.17M1.34B1.27B1.34B
Total Debt232.54M38.75M2.84M5.90M17.86M34.42M
Total Liabilities723.80M477.80M341.82M232.96M181.45M124.83M
Stockholders Equity2.81B1.53B1.79B1.84B1.79B1.90B
Cash Flow
Free Cash Flow630.61M530.62M434.78M415.91M313.61M131.04M
Operating Cash Flow631.54M536.35M440.34M421.74M319.20M135.69M
Investing Cash Flow68.80M134.27M-23.46M61.60M-287.31M-296.83M
Financing Cash Flow-289.49M-750.13M-451.64M-500.47M-319.43M733.36M

Ever Supreme Bio Technology Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:6712 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:6712TW:671273OutperformTWD 14.92B30.86―2.14%13.26%-15.91%
TW:1789TW:178957NeutralTWD 16.01B904.98―1.45%-4.75%-90.91%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

0%200%400%TW:6712TW:1789TW:6586TW:6589TW:7729TW:7827Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:6712 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:6712Ever Supreme Bio Technology Co., Ltd.148.00-5.31-3.46%
TW:1789Scinopharm Taiwan, Ltd.20.002.6014.92%
TW:6586CHO Pharma, Inc.76.2046.15153.58%
TW:6589EirGenix, Inc.51.70-30.20-36.87%
TW:7729Steminent Biotherapeutics, Inc.247.00204.75484.55%
TW:7827HanchorBio Inc.119.0049.0070.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026